<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>) and naso-pharyngeal <z:mp ids='MP_0002038'>carcinoma</z:mp> (NPC) are <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> generally believed to be associated with Epstein-Barr virus (EBV) </plain></SENT>
<SENT sid="1" pm="."><plain>Algerian population could be considered at high risk for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">BL</z:e>-EBV association </plain></SENT>
<SENT sid="2" pm="."><plain>In a series of 34 BL patients observed by us between 1982 and 1984 characteristics were: 70% of children were under 5 years age, abdominal location in 90% of cases (n = 30), 13% only isolated, massive <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> burden (70% stage III after Murphy, 30% stage IV after Murphy and Duque-Hammershaimb), EBV serology titers above or equal to 640 in 60% of cases (anti-EBNA and anti-VCA) and 50% (anti-EA) respectively, presence of EBNA antigen in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cells found in 63% of cases, no complete correlation between serology positivity and EBNA presence </plain></SENT>
</text></document>